Epstein-Barr virus (EBV)–associated non-Hodgkin lymphoma (NHL).
| Type of NHL . | Target Cell . | EBV Frequency . | Latency . |
|---|---|---|---|
| Abbreviations: CNS, central nervous system; HIV, human immunodeficiency virus; SCAEBV, severe chronic active EBV infection | |||
| Immunosuppressed Patients | |||
| NHL associated with primary immunodeficiency | B cell | > 95% | III |
| Post transplant lymphoma | |||
| Hematopoietic stem cell transplant | B cell | > 95% | III |
| Solid organ transplant | B cell | > 95% in first year post-transplant, 70%–80% after 1 year | Usually III but late lymphomas may be II or I |
| HIV-associated lymphomas | |||
| Primary CNS lymphoma | B cell | > 95% | III |
| Primary effusion lymphoma | B cell | > 90% | I |
| Diffuse large cell lymphoma | B cell | 30%–60% | II or I |
| Burkitt’s lymphoma | B cell | 30%–60% | I |
| Methotrexate-induced lymphomas | B cell | > 95% | III |
| Immunocompetent Patients | |||
| Extranodal NK-T cell lymphoma | NK cell with some T cell-associated antigens | > 95% | II |
| Aggressive NK leukemia lymphoma | NK cell with some T cell-associated antigens | 30%–60% | II or I |
| SCAEBV | T and NK and B cells | > 95% | II |
| Lymphatoid granulomatosis | B cell | 80%–95% | II |
| Diffuse large B cell lymphoma and CD30+ Ki-1+ anaplastic large cell lymphoma | B cell | 10%–35% | II |
| T cell rich B cell lymphoma | B cell | 20% | II |
| Angioimmunoblastic lymphoma | B cells and T cells | > 80% | II |
| Type of NHL . | Target Cell . | EBV Frequency . | Latency . |
|---|---|---|---|
| Abbreviations: CNS, central nervous system; HIV, human immunodeficiency virus; SCAEBV, severe chronic active EBV infection | |||
| Immunosuppressed Patients | |||
| NHL associated with primary immunodeficiency | B cell | > 95% | III |
| Post transplant lymphoma | |||
| Hematopoietic stem cell transplant | B cell | > 95% | III |
| Solid organ transplant | B cell | > 95% in first year post-transplant, 70%–80% after 1 year | Usually III but late lymphomas may be II or I |
| HIV-associated lymphomas | |||
| Primary CNS lymphoma | B cell | > 95% | III |
| Primary effusion lymphoma | B cell | > 90% | I |
| Diffuse large cell lymphoma | B cell | 30%–60% | II or I |
| Burkitt’s lymphoma | B cell | 30%–60% | I |
| Methotrexate-induced lymphomas | B cell | > 95% | III |
| Immunocompetent Patients | |||
| Extranodal NK-T cell lymphoma | NK cell with some T cell-associated antigens | > 95% | II |
| Aggressive NK leukemia lymphoma | NK cell with some T cell-associated antigens | 30%–60% | II or I |
| SCAEBV | T and NK and B cells | > 95% | II |
| Lymphatoid granulomatosis | B cell | 80%–95% | II |
| Diffuse large B cell lymphoma and CD30+ Ki-1+ anaplastic large cell lymphoma | B cell | 10%–35% | II |
| T cell rich B cell lymphoma | B cell | 20% | II |
| Angioimmunoblastic lymphoma | B cells and T cells | > 80% | II |